LDS/Medical Tests/Norpropoxyphene, Urine

Norpropoxyphene, Urine

Norpropoxyphene is a mild analgesic that is very similar to methadone pharmacologically. It is the major metabolite of propoxyphene (dextropropoxyphene). Propoxyphene is rapidly metabolized into norapropoxyphene, which is an active metabolite that can produce harmful effects due to its longer half-life. The half-life of norpropoxyphene is 8-24 hours. The duration of analgesia is 4-5 hours. Typical route of administration is oral.

Propoxyphene and norpropoxyphene can elicit the following effects: euphoria, sedation, mental clouding, amnesia, hostility, irritability, and vivid or disturbing dreams. Overdose effects include respiratory depression, nausea, vomiting, constipation, hypothermia, seizure, hypotension, coma, and possible death.

The Food and Drug Administration has announced in 2010 that prescriptions containing medications were being withdrawn from the US market. Unfortunately, its non-approved use and abuse remains somewhat common.

  • Therapeutic monitoring
  • Postoperative analgesia
  • Monitoring management of chronic pain associated with cancer or other terminal illness
  • Drug abuse evaluation
  • Toxicity assessment
A qualitative positive result from an immunoassay type test indicates only the presence of Propoxyphene and norpropoxyphene and does not necessarily correlate with the extent of physiological and psychological effects. Any positive result should be confirmed by a non-immunological method such as GC, LC/MS or GC/MS.

Therapeutic Level 200-2200 ng/ml

Toxic level: Not determined

Note: therapeutic ranges and toxic thresholds are best evaluated from blood samples. Quantitative results obtained with blood samples collected at specific times after drug administration are preferred for pharmacokinetic analyses     

 

Cut-Off Ranges

Cut-off values can vary based on the particular method of analysis that is used for detection by a quantitative method, such as LC/MS or GC/MS. The testing laboratory cut-off range is listed on the patient report. Consult your physician for further information or click on one of the references that are listed below.

Liquid Chromatography/Mass Spectroscopy (LC/MS) or Gas Chromatography/Mass Spectroscopy (GC/MS). The preferred method of detection is LC/MS. The main method of quantitation detection is via LC/MS or LC/MS/MS (liquid chromatography coupled with mass spectroscopy).

Fresh urine specimen collected in either a clean glass or plastic container. An acceptable urine specimen submitted for testing should be in the pH range of 3-11. Adulteration of the urine specimen can result in erroneous results.

Stability

  • Ambient: 3-5 days
  • Refrigeration: 5-7 days
  • Frozen: 30 days
Pharmacogenetic testing such as genotyping for *CYP3A4, CYP3A5, CYP2D6, CYP2C9, CYP2C19,* COMT and *OPRM1* variants could guide drug and dose selection. Supportive testing such as a liver profile, kidney profile, comprehensive metabolic panel, CBC, and testing for concomitant drugs may be appropriate.
1-3 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • Baselt RC (ed). Analytical procedures for therapeutic drug monitoring and emergency toxicology, 2nd ed. Littleton, MA: PSG Publishing Co.; 1987.
  • Baselt RC (ed). Disposition of toxic drugs and chemicals in man, 9th ed. Foster City, CA: Biomedical Publications; 2011.
  • Baselt RC (ed). Disposition of toxic drugs and chemicals in man, 6th ed. Foster City, CA: Biomedical Publications; 2002.
  • Gupta RN. Review: drug level monitoring: sedative hypnotics. J Chromatography. 1985;340:139-72. L
  • evine B (ed). Principles of Forensic Toxicology, 4th Edition. Washington DC: AACC Press. Chapter 14, Miscellaneous Central Nervous System Depressants. 261-270; 2013.
  • Brunton LL, Chabner B, Knollman B (eds). Goodman and Gilmans’ the pharmacological basis of therapeutics, 12th ed. New York: McGraw-Hill; 2010.
  • Cooper FJ, Logan BK. Drugs and human performance fact sheets. Washington, DC: National Highway Traffic Safety Administration, U.S. Department of Transportation. DOT HS 809 725; 2004.
  • Katzung BG, Masters S, Trevor AK (eds). Basic and clinical pharmacology, 12th ed. New York: McGraw-Hill; 2011.
  • Stout PR, Farrell LJ. Opioids – Effects on human performance and behavior. Forensic Sci Rev. 2002;15:29-59.
  • Wu A (ed). Tietz, clinical guide to laboratory test, 4th ed. Philadelphia:WB Saunders; 2006.